Pfizer & BioNTech’s vaccine authorized for EU use by European Medicines Agency



Less than two weeks after it was approved for use in the U.S., Europe’s regulator, the European Medicines Agency authorized conditional approval of Pfizer and BioNTech’s coronavirus vaccine.

 Many countries in the EU including France, Germany, Italy and Austria aim to begin using the vaccine from December 27, after it is endorsed by the European Commission.

 The European Medicines Agency released a statement saying that it had recommended conditional marketing authorization for the Pfizer vaccine to be used on people whose ages were 16 years or above.

 The agency said, “EMA’s scientific opinion paves the way for the first marketing authorization of a COVID-19 vaccine in the EU by the European Commission, with all the safeguards, controls and obligations this entails.”

 Lockdowns are tightening across the EU as a deadly coronavirus wave, exacerbated by winter, is sweeping across, as well as mutating to form more infectious strains. A new and highly transmissible mutation of the virus has been reported in the U.K. leading to flights and vehicular movement being banned from or to Britain.

 The death toll across Europe is almost half a million. Governments are trying to strategize not only to prevent new infections and deaths but also to safeguard the economy as the virus has taken a huge physiological and economic toll across the world. With the holiday season around the corner, the infections and deaths are expected to rise much further.


Follow us on Google news for more updates and News


This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.